CONTINUOUS SUBCUTANEOUS INFUSION VERSUS MULTIPLE DOSE INJECTION OF INSULIN FOR NEWLY-DIAGNOSED T1D PAEDIATRIC PATIENTS- A COST-UTILITY ANALYSIS

Author(s)

Ridyard CH1, Blair J2, Hughes DA1, on behalf of the SCIPI Trial Investigators .3
1Bangor University, Bangor, UK, 2Alder Hey Children's NHS Foundation Trust, Liverpool, UK, 3Clinical Trials Research Centre, Liverpool, UK

OBJECTIVES: Continuous subcutaneous insulin infusions (CSII) and multiple daily injections (MDI) with insulin are alternative methods of glycaemic control in type 1 diabetes (T1D) aimed to reduce the risk of developing long term microvascular and macrovascular complications. The SCIPI trial (ISRCTN29255275) compared the clinical and cost-effectiveness of CSII treatment with MDI in paediatric patients from the perspective of the NHS. METHODS: Children (aged 7months-15years) with newly-diagnosed T1D were randomised equally to CSII or MDI for treatment and stratified by age and treatment centre. Resource use (prescribed insulin, concomitant medications, devices, consumables, inpatient, outpatient, emergency, adverse events, general practitioner and school visits) was collected at randomisation, 3, 6, 9 and 12 month intervals. Quality adjusted life years (QALYs) were assessed by the Health Utilities Index (Mark II) completed at all study visits. RESULTS:

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PMD58

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×